Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ramsay Generale denteFRA:GD6 -0.46%71 EV-to-EBITDA is 7.56 as of Jul. 27, 2026, which is 50% below its 10-year median of 15.11. GuruFocus rates FRA:GD6 with a GF Score™ of 71/100 and a GF Value™ of €21.83. The stock has 8 warning signs investors should review. Among 509 Healthcare Providers & Services companies, Ramsay Generale dente ranks better than 69.16% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ramsay Generale dente's enterprise value is €5,021 Mil.
Ramsay Generale dente's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €664 Mil. Therefore, Ramsay Generale dente's EV-to-EBITDA for today is 7.56.
The historical rank and industry rank for Ramsay Generale dente's EV-to-EBITDA or its related term are showing as below:
FRA:GD6'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -30.45 Med: 15.11 Max: 15.88
Current: 7.56
During the past 13 years, the highest EV-to-EBITDA of Ramsay Generale dente was 15.88. The lowest was -30.45. And the median was 15.11.
FRA:GD6's EV-to-EBITDA is ranked better than 69.16% of 509
companies
in the Healthcare Providers & Services industry
Industry Median: 10.97
vs FRA:GD6: 7.56
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Ramsay Generale dente (FRA:GD6) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ramsay Generale dente's PE Ratio (TTM) for today is calculated as:
Ramsay Generale dente's share price for today is €10.75.
Ramsay Generale dente's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.071.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Ramsay Generale dente EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Ramsay Generale dente's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Ramsay Generale dente's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ramsay Generale dente EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Ramsay Generale dente's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ramsay Generale dente's EV-to-EBITDA falls into.
Ramsay Generale dente's current Enterprise Value is €5,021 Mil.
Ramsay Generale dente's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €664 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ramsay Generale dente (FRA:GD6) has a EV-to-EBITDA of 7.56 as of Jul. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ramsay Generale dente. This is 50% below median its historical median of 15.11. According to the industry distribution chart, Ramsay Generale dente ranks #157 out of 509 companies in the Healthcare Providers & Services industry, placing it in the top 30.8%.
Is Ramsay Generale dente's EV-to-EBITDA too high?
Ramsay Generale dente's current EV-to-EBITDA of 7.56 is 50% below median its 10-year median of 15.11. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.97. Ramsay Generale dente's value of 7.56 is 31.1% below this industry median. Based on the distribution chart, Ramsay Generale dente ranks #157 out of 509 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Ramsay Generale dente has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Ramsay Generale dente's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Ramsay Generale dente ranks #157 out of 509 companies for EV-to-EBITDA. This puts Ramsay Generale dente in the upper half of its industry. The industry median EV-to-EBITDA is 10.97. Ramsay Generale dente's value of 7.56 is 31.1% below this benchmark. While the company's 10-year median is 15.11 vs. the industry median of 10.97, Ramsay Generale dente has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.97, based on 509 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ramsay Generale dente's current EV-to-EBITDA of 7.56 is 31.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ramsay Generale dente. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ramsay Generale dente's current EV-to-EBITDA is 7.56, which is 50% below median its own 10-year median of 15.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ramsay Generale dente stock overvalued right now?
Ramsay Generale dente (FRA:GD6) has a current EV-to-EBITDA of 7.56. The stock's GF Value™ is €21.83, compared to a current price of €10.75 — trading 50.8% below its estimated fair value. The current EV-to-EBITDA is 7.56, which is 50% below median its 10-year median of 15.11 and 31.1% below the Healthcare Providers & Services industry median of 10.97. Ramsay Generale dente's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Ramsay Generale dente (FRA:GD6), the current EV-to-EBITDA is 7.56 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ramsay Generale dente (FRA:GD6) Overvalued in 2026?
Based on GuruFocus' analysis, Ramsay Generale dente stock appears to be undervalued.
The current stock price of €10.75 is trading 50.8% below its estimated GF Value™ of €21.83.
Key valuation signals for FRA:GD6:
EV-to-EBITDA: 7.56 (50% below median its 10-year median of 15.11)
GF Value™: €21.83 vs. price of €10.75 (50.8% below fair value)
Industry Position: 31.1% below the Healthcare Providers & Services median (#157 of 509)
No single metric tells the full story. See the FRA:GD6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ramsay Generale de Sante SA operates in the private healthcare sector in France. The company provides a comprehensive range of patient care services in thirteen business segments: Nouvelle Aquitaine, Bourgogne-Franche Comte, Brittany, Centre-Val de Loire, Hauts de France, Normandy, Provence Alpes Cote d'Azur, Ile de France, Auvergne-Rhone Alpes, Occitanie, Italy, Nordics, and Head Office. It generates maximum revenue from the Ile de France segment. The company also specializes in cardiology, heart surgery, digestive surgery, dermatology, urology, ophthalmology, vascular and endovascular surgery.
71GF Score
Get the complete analysis for FRA:GD6
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GD6 has been successfully added to your 
